Financial Performance - In Q1 2023, the company achieved operating revenue of CNY 561 million, a decrease of 7.28% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 164 million, reflecting a growth of 4.94% year-on-year[5] - The subsidiary, Shandong Dain Marine Biological Pharmaceutical Co., Ltd., reported operating revenue of CNY 550 million and net profit of CNY 315 million, with year-on-year increases of 2.98% and 10.13%, respectively[4] - Total operating revenue for Q1 2023 was CNY 561,439,253.57, a decrease of 7.26% compared to CNY 605,516,557.27 in Q1 2022[15] - Net profit for Q1 2023 was CNY 314,399,174.09, representing an increase of 6.00% from CNY 294,239,667.77 in Q1 2022[15] - The company reported a net profit attributable to shareholders of CNY 163,725,554.07 for Q1 2023, compared to CNY 156,021,080.23 in Q1 2022, reflecting an increase of approximately 4.3%[16] - Total comprehensive income for Q1 2023 was CNY 314,399,174.09, compared to CNY 294,239,667.77 in Q1 2022, indicating an increase of approximately 6.8%[16] Cash Flow and Liquidity - The net cash flow from operating activities increased by 21.41% to CNY 335 million compared to the previous year[5] - Net cash flow from operating activities for Q1 2023 was CNY 335,465,224.39, up from CNY 276,299,060.18 in the same period last year, indicating a growth of about 21.4%[16] - The company experienced a net cash outflow from investing activities of CNY -106,073,536.81 in Q1 2023, compared to a net inflow of CNY 46,462,512.22 in Q1 2022[16] - Cash flow from financing activities showed a net outflow of CNY -235,465,952.17 in Q1 2023, contrasting with a net inflow of CNY 3,842,061.89 in Q1 2022[17] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 1,732,064,421.56, a decrease from CNY 1,528,339,147.89 at the end of Q1 2022[17] Assets and Liabilities - Total assets at the end of Q1 2023 reached CNY 4.82 billion, up 2.73% from the end of the previous year[5] - The company's total assets increased to CNY 4,818,661,151.84, up from CNY 4,690,492,822.90 at the end of Q1 2022[14] - Total liabilities rose to CNY 947,209,068.42, compared to CNY 629,027,439.57 in the same period last year[14] - The equity attributable to shareholders increased by 6.34% to CNY 2.75 billion compared to the end of the previous year[5] - The equity attributable to shareholders of the parent company increased to CNY 2,747,813,822.68, up from CNY 2,584,088,268.61 year-over-year[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 19,304[11] - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of shares, totaling 51,544,340 shares[11] - The company reported a total of 10 major shareholders with varying percentages of ownership, the largest being 22.00%[11] Other Financial Metrics - The company reported a significant increase in accounts receivable by 65.17% to CNY 89.52 million, primarily due to the increase in receivables from the subsidiary[8] - Other receivables surged by 100.93% to CNY 19.04 million, attributed to increased government subsidy receivables[8] - The company experienced a 603.93% increase in other income, totaling CNY 14.91 million, mainly due to higher government subsidies[8] - The company’s basic earnings per share rose by 4.48% to CNY 0.70 per share[5] - Basic and diluted earnings per share for Q1 2023 were both CNY 0.70, up from CNY 0.67 in Q1 2022, marking a growth of about 4.5%[16] Research and Development - Research and development expenses for Q1 2023 were CNY 11,073,221.93, a decrease from CNY 12,769,669.95 in Q1 2022[15] Future Outlook - Future outlook includes continued focus on market expansion and new product development to drive growth[15]

证券代码：000915 证券简称：华特达因 | 挂，已经比大股东增持 1%的时候低，请问大股东有增持计划 | | --- | | 吗？ | | 答：您好，公司目前没有接到大股东的增持计划。 | | 5.问：公司今年会被纳入医药集采么？除了伊可新外，其 | | 他产品年度业绩目标如何？ | | 答：您好，除伊可新等主要产品外，右旋糖酐铁颗粒及复 | | 方碳酸钙泡腾颗粒也是公司 2023 年重点推广产品。 | | 6.问：请问专注医药主营的具体措施，有没有同行业并购 | | 计划，剥离非医药的进程。 | | 答：您好。公司专注儿童制药及健康领域，对非主业将在 | | 发展的基础上择机退出。如有符合企业发展战略的并购标的， | | 公司不排除通过并购方式实现快速发展。 | | 7.问：公司第一季度销售状况？ | | 答：您好，关于公司 2023 年第一季度经营情况，请您关 | | 注公司 2023 年第一季度报告。 | | 8. 问：关心下一代健康成长是中华人民长治久安的根本 | | 前提，也是中华人民尊老爱幼优良传统，请问：（1）公司未 | | 来如何布局儿童健康成长产业，有哪些前瞻设想，并已经开始 | | 了 ...

证券代码：000915 证券简称：华特达因 公告编号：2023-011 山东华特达因健康股份有限公司 关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）定于 2023 年 3 月 30 日（周四）16:00-17:00 在全景网举办 2022 年年度报告业 绩说明会，本次业绩说明会将采用网络远程的方式举行，投资者可登 陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次 年度业绩说明会。 公司出席本次说明会的人员有：总经理杨杰女士、独立董事吕玉 芹女士、董事会秘书范智胜先生、财务负责人王伟女士。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可于 2023 年 3 月 29 日（ 星 期 三 ） 15 ： 00 前访问 https://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页 面。公司将在 2022 年度业绩说明会上，对投资者 ...

Financial Performance - The company's operating revenue for 2022 was CNY 2,341,007,595.24, representing a 15.49% increase from CNY 2,027,141,972.94 in 2021[17]. - Net profit attributable to shareholders for 2022 was CNY 526,864,048.18, a 38.55% increase from CNY 380,262,703.21 in 2021[17]. - The net profit after deducting non-recurring gains and losses for 2022 was CNY 529,093,490.75, up 48.51% from CNY 356,264,194.12 in 2021[17]. - The net cash flow from operating activities for 2022 was CNY 1,196,404,539.42, an increase of 58.29% compared to CNY 755,852,593.24 in 2021[17]. - The total assets at the end of 2022 were CNY 4,690,492,822.90, a 19.19% increase from CNY 3,935,426,876.63 at the end of 2021[17]. - The weighted average return on net assets for 2022 was 22.11%, an increase of 4.02 percentage points from 18.09% in 2021[17]. - The basic earnings per share for 2022 was CNY 2.25, reflecting a 38.89% increase from CNY 1.62 in 2021[17]. - The company reported a total of CNY 7,566,620.42 in government subsidies for 2022, down from CNY 11,451,906.08 in 2021[23]. - The company achieved a total operating revenue of CNY 2.34 billion in 2022, representing a year-on-year growth of 15.49%[36]. - The revenue from pharmaceutical products reached CNY 2.04 billion, accounting for 87.18% of total operating revenue, with a year-on-year increase of 38.58%[38]. - The net profit attributable to the parent company was CNY 527 million, reflecting a strong performance amidst market challenges[36]. Market and Business Strategy - The company is committed to enhancing its research and development capabilities for new products and technologies[12]. - The management discussed future development prospects, emphasizing the importance of innovation and market expansion strategies[12]. - The company aims to expand its market share in pediatric pharmaceuticals through innovative product development and strategic marketing[30]. - The company is focused on R&D for pediatric medications, with a commitment to developing tailored pharmaceutical solutions[37]. - The company is actively exploring market expansion opportunities but did not disclose specific new products or technologies in the current report[70]. - The company plans to enhance its core capabilities and maintain a focus on high-quality development, aligning with national policies to support children's health[78]. - The company is committed to exiting non-core businesses while ensuring that the transition does not adversely affect overall performance[78]. - The company is focused on expanding its market presence with innovative health products tailored for specific consumer groups[32]. - The company is exploring potential mergers and acquisitions to accelerate growth and expand its product offerings[178]. Research and Development - The company is actively involved in the research and development of pediatric drugs, addressing the shortage of specialized medications for children[27]. - The company has established a robust R&D team of over 100 professionals dedicated to pediatric drug development, with a significant number of products in the pipeline[36]. - The company has received clinical trial notifications for multiple new drug candidates, indicating a robust pipeline for future growth[53]. - The company is investing 50 million RMB in research and development for new technologies aimed at improving product efficacy and customer satisfaction[90]. - The company has implemented a strategy to enhance the quality and safety of children's medications, ensuring compliance with regulatory standards[28]. Governance and Compliance - The company is committed to improving its corporate governance structure, ensuring compliance with relevant laws and regulations[81]. - The company has established a clear division of responsibilities among its governance bodies, enhancing operational independence from controlling shareholders[81]. - The company emphasizes fair treatment of all investors and timely disclosure of information as part of its governance practices[81]. - The company maintained a high level of transparency in investor relations, receiving an A rating for its information disclosure practices in 2022[83]. - The company has engaged with various institutional investors, including Guangfa Securities and CCB International, during its conference calls[79]. Environmental Responsibility - The company invested approximately 2.7 million in environmental protection measures during the reporting period to reduce carbon emissions[115]. - The wastewater treatment system operates smoothly, utilizing physical sedimentation and activated sludge methods to ensure compliance with discharge standards[115]. - The company has implemented automatic online monitoring systems for wastewater, soil, and noise to ensure compliance with environmental standards[115]. - The company has committed to enhancing employee awareness of energy conservation and reducing resource waste through educational initiatives[116]. Shareholder Information - The total share capital of the company is 234,331,480 shares, with a cash dividend of 8 RMB per share proposed for distribution[4]. - The company has not issued any bonus shares or capital reserves for the year 2022[4]. - The company has a total of 6 independent directors, with one independent director resigning in April 2022 for personal reasons[88]. - The company’s overall shareholding structure remains stable, with no significant changes in the control of major shareholders during the reporting period[150]. - The largest shareholder, Shandong Huate Holding Group Co., Ltd., holds 22.00% of the shares, totaling 51,544,340 shares[154]. Financial Management - The company has completed the internal control system revision and established a comprehensive internal control management framework to enhance operational risk prevention and management efficiency[108]. - The internal control audit report confirms that the company maintained effective internal control over financial reporting as of December 31, 2022[111]. - The company has not reported any penalties from regulatory authorities in the last three years[95]. - The company’s financial statements were reviewed and approved by the auditing firm, ensuring compliance and accuracy[102]. - The audit opinion for the financial statements was unqualified, indicating that the financial reports fairly represent the company's financial position[163].

证券代码：000915 证券简称：山大华特 编号：2015-001 山东山大华特科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|-------------------------|-------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称 | | 出席股东大会现场会议的股东、民族证券张树生、民生加银基金蒯 | | 及人员姓名 | 学章、阳光保险王晓君、 | 星石投资方磊等 | | 时间 | 2015 年 3 月 12 | 日下午 | | 地点 | 公司会议室 | | | 上市公司接待 | | 公司董事长张兆亮主持，参加股东大会的公司董事、监事、高管人 | | 人员姓名 | 员参加 | | | 投资者关系活 | 公司于 2015 | 年 3 月 ...

证券代码：000915 证券简称：山大华特 编号：2016-001 山东山大华特科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |--------------|-------------------------|------------------------------------------------------------| | | | | | 投资者关系活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □其他 | | | 参与单位名称 | | 出席股东大会现场会议的股东、汇添富基金林小伟、华夏基金刘志 | | 及人员姓名 | 军、中银基金陈哲、 | 民生证券刘淼等 28 人 | | 时间 | 2016 年 5 月 25 | 日下午 | | 地点 | 公司会议室 | | | 上市公司接待 | | 公司董事长张兆亮主持，参加股东大会的公司董事、监事、高管人 | | 人员姓名 | 员参加 | | | 投资者关系活 | 公司于 2016 | 年 5 ...

证券代码：000915 证券简称：山大华特 编号：2018-001 山东山大华特科技股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|---------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | □其他 | | | 参与单位名称及 | | 国投瑞银基金管理有限公司 谢允昌 上海重阳投资管理股份有 | | 人员姓名 | | 限公司 胡敏 深圳市金田龙盛投资管理有限公司 杨丙田 深圳 | | | | 市岭南资本投资管理有限公司 张宪强 | | 时间 | 2018 年 11 月 | 29 日 | | 地点 | 公司四楼会议室 | | | 上市公司接待人 | 董事会秘书 范智胜 | | | 员姓名 | 证券事务代表 田波 | | | 投资者关系活动 | ...

证券代码：000915 证券简称：华特达因 山东华特达因健康股份有限公司投资者关系活动记录表 编号：2021-005 | --- | --- | --- | --- | |----------------------------------------------|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | 投 资 者关 系 活 动 类别 | ■特定对象调研 \n□媒体采访 □新闻发布会 □现场参观 | □分析师会议 \n□业绩说明会 □路演活动 □其他 | | | 参 与 单位 名 称 及人员姓名 | 洪泰海创 王鹏 | 洪泰海创 夏瑜 | | | ...